Beijing Sun Novo Pharmaceutical Research Co Ltd (688621) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Beijing Sun Novo Pharmaceutical Research Co Ltd (688621) has a cash flow conversion efficiency ratio of 0.065x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥76.07 Million ≈ $11.13 Million USD) by net assets (CN¥1.17 Billion ≈ $170.51 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Beijing Sun Novo Pharmaceutical Research Co Ltd - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Beijing Sun Novo Pharmaceutical Research Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 688621 total liabilities for a breakdown of total debt and financial obligations.
Beijing Sun Novo Pharmaceutical Research Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Beijing Sun Novo Pharmaceutical Research Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
HELIA GROUP LTD.
F:0GI0
|
N/A |
|
Kvutzat Acro Ltd.
TA:ACRO
|
-0.030x |
|
ChengDa Pharmaceuticals Co. Ltd.
SHE:301201
|
N/A |
|
NB Bancorp, Inc. Common Stock
NASDAQ:NBBK
|
0.028x |
|
Shanxi Guoxin Energy Co Ltd A
SHG:600617
|
0.151x |
|
Citic Press Corp
SHE:300788
|
0.020x |
|
Wushang Group Co Ltd
SHE:000501
|
0.033x |
|
Cartrade Tech Limited
NSE:CARTRADE
|
0.008x |
Annual Cash Flow Conversion Efficiency for Beijing Sun Novo Pharmaceutical Research Co Ltd (2017–2024)
The table below shows the annual cash flow conversion efficiency of Beijing Sun Novo Pharmaceutical Research Co Ltd from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see Beijing Sun Novo Pharmaceutical Research stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥1.10 Billion ≈ $161.35 Million |
CN¥32.02 Million ≈ $4.69 Million |
0.029x | -66.94% |
| 2023-12-31 | CN¥1.06 Billion ≈ $154.71 Million |
CN¥92.86 Million ≈ $13.59 Million |
0.088x | -23.27% |
| 2022-12-31 | CN¥908.23 Million ≈ $132.90 Million |
CN¥103.96 Million ≈ $15.21 Million |
0.114x | -0.18% |
| 2021-12-31 | CN¥769.64 Million ≈ $112.62 Million |
CN¥88.25 Million ≈ $12.91 Million |
0.115x | -64.88% |
| 2020-12-31 | CN¥192.92 Million ≈ $28.23 Million |
CN¥62.99 Million ≈ $9.22 Million |
0.327x | -31.94% |
| 2019-12-31 | CN¥118.76 Million ≈ $17.38 Million |
CN¥56.97 Million ≈ $8.34 Million |
0.480x | -19.71% |
| 2018-12-31 | CN¥73.82 Million ≈ $10.80 Million |
CN¥44.11 Million ≈ $6.45 Million |
0.597x | +147.99% |
| 2017-12-31 | CN¥33.25 Million ≈ $4.87 Million |
CN¥8.01 Million ≈ $1.17 Million |
0.241x | -- |
About Beijing Sun Novo Pharmaceutical Research Co Ltd
Beijing Sun-Novo Pharmaceutical Research Co., Ltd., a contract research company, engages in the research and development of drugs in China. The company operates external preparation platform that focuses on the research and development of new drugs and generic drugs for skin external preparations; children's clinical data bridging research center; pediatric drug research and development platform;… Read more